AC Immune SA vs Camp4 Therapeutics
AC Immune SA is the larger business, with $4.3m of revenue in fiscal 2025 against $3.5m for Camp4 Therapeutics (1.2 times as much). Camp4 Therapeutics grew faster (436.5% against -86.1%). AC Immune SA kept more of each dollar of sales as profit: a net margin of -1971.6% against -2298.5%. AC Immune SA carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AC Immune SAACIU, 2025 | Camp4 TherapeuticsCAMP, 2025 |
|---|---|---|
| Revenue | $4.3m | $3.5m |
| Revenue growth | -86.1% | 436.5% |
| Net income | −$85.0m | −$80.4m |
| Operating margin | -1940.1% | -1502.4% |
| Net margin | -1971.6% | -2298.5% |
| Return on equity | -94.3% | -145.1% |
| Free cash flow | −$84.7m | −$29.8m |
| Cash | $33.8m | $110m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 48 |
| Market value | $213m | $201m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 2 sales | 5 buys, 6 sales |